These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 12627352)

  • 1. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
    Lai CL; Dienstag J; Schiff E; Leung NW; Atkins M; Hunt C; Brown N; Woessner M; Boehme R; Condreay L
    Clin Infect Dis; 2003 Mar; 36(6):687-96. PubMed ID: 12627352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
    Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
    J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.
    Gauthier J; Bourne EJ; Lutz MW; Crowther LM; Dienstag JL; Brown NA; Condreay LD
    J Infect Dis; 1999 Dec; 180(6):1757-62. PubMed ID: 10558928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
    Hashimoto Y; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saito S; Suzuki Y; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):684-91. PubMed ID: 20166170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy of chronic hepatitis B with lamivudine.
    Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH
    Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.
    Papatheodoridis GV; Dimou E; Laras A; Papadimitropoulos V; Hadziyannis SJ
    Hepatology; 2002 Jul; 36(1):219-26. PubMed ID: 12085368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B; Wei L; Chen M; Wang L
    Microbiol Res; 2008; 163(4):487-92. PubMed ID: 17317127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.
    Buti M; Sánchez F; Cotrina M; Jardi R; Rodríguez F; Esteban R; Guardia J
    J Infect Dis; 2001 Apr; 183(8):1277-80. PubMed ID: 11262212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.